Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05509023 |
Recruitment Status :
Recruiting
First Posted : August 19, 2022
Last Update Posted : February 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atopic Dermatitis | Drug: ADX-914 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 102 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis |
Actual Study Start Date : | September 30, 2022 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: ADX-914 |
Drug: ADX-914
Subcutaneous administration of ADX-914 |
Placebo Comparator: Placebo |
Drug: Placebo
Subcutaneous administration of Placebo |
- Part A only: Safety parameters including incidence of serious adverse events and adverse events of special interest [ Time Frame: 14 Weeks ]
- Part A and B: Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 14 for ADX-914 vs placebo [ Time Frame: 14 Weeks ]Severity score is based on evaluation of severity of atopic dermatitis in 4 body regions (head and neck, trunk, upper limbs, and lower limbs). The minimum score is 0 (less severe) and maximum score is 72 (most severe).
- Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score [ Time Frame: 24 Weeks ]Severity score is based on evaluation of severity of atopic dermatitis in 4 body regions (head and neck, trunk, upper limbs, and lower limbs). The minimum score is 0 (least severe) and maximum score is 72 (most severe)
- Mean percentage change from baseline in Scoring Atopic Dermatitis (SCORAD) score [ Time Frame: 24 Weeks ]Score is based on evaluation of 6 body regions (Head and neck, upper limbs, lower limbs, anterior trunk, back, and genitals). The minimum score is 0% (least severe) and the maximum score is 100% (most severe)
- Proportion of subjects achieving Eczema Area and Severity Index (EASI) reduction of 50%, 75% and 90% [ Time Frame: 24 Weeks ]Severity score is based on evaluation of severity of atopic dermatitis in 4 body regions (head and neck, trunk, upper limbs, and lower limbs). The minimum score is 0 (least severe) and maximum score is 72 (most severe)
- Proportion of subjects achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0 or 1 with at least 2 grades of reduction from Baseline [ Time Frame: 24 Weeks ]Score is based on Investigator's impresion of the severity of Atopic Dermatitis with 0 being the least severe and 4 being the most severe
- Incidence of adverse events [ Time Frame: 24 Weeks ]As evaluated by vital signs, physical examinations, laboratory evaluations, and 12-lead electrocardiograms
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥18 years, inclusive, at time of informed consent, with chronic AD (duration of disease ≥3 years) diagnosed by the Eichenfield revised criteria of Hanifin and Rajka.
-
Moderate to severe disease activity at baseline and screening defined as:
- BSA affected ≥10%
- EASI Score ≥12
- Investigators Global Score (IGA) ≥3
-
Who, in the opinion of the Investigator, have a history of inadequate response to at least one of the following:
- at least 4-week course of medium-potency topical steroids or other approved topical immunomodulators (calcineurin, PDE-4 and JAK inhibitors)
- systemic steroids or phototherapy
- oral chemical synthetic immunomodulators (MTX, mycophenolate mofetil, azathioprine, cyclosporine, systemic approved biologics [dupliumab, ustekinumab or tralokinumab]), or approved systemic targeted synthetic JAK inhibitors (upadacitinib, abrocitinib)
Exclusion Criteria:
- Body weight ≤ 50.0 kg for men and ≤ 45.0 kg for women and > 120 kg at Screening
- Rescue therapy, topical or systemic, need anticipated within 4 weeks of randomization
- Recent (within 2 months of informed consent) or current clinically serious viral, bacterial, fungal, or parasitic infection or mycobacterial infection
- A positive QuantiFERON®TB Gold test at Screening or history of tuberculosis (TB)
- Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to receive a live vaccine during the study
- Systemic, topical or device-based therapy of AD
- Serious concomitant illness that could require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring
- Other concomitant skin conditions that would interfere with evaluations of the effect of study medication on atopic dermatitis
- Other active autoimmune diseases other than those above that would make it difficult to appropriately assess AD disease activity or pose a risk to the subject's participation in the trial
- Pregnant or lactating women, or women planning to become pregnant or initiate breastfeeding.
- History of sensitivity to any of the study treatments, or components thereof, or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates their participation.
- Has been in another investigational trial within 30 days or 5 half-lives of the investigational agent (whichever is greater) prior to the informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05509023
Contact: Kristin Orr | 9193950132 | korr@q32bio.com |
Responsible Party: | Q32 Bio Inc. |
ClinicalTrials.gov Identifier: | NCT05509023 |
Other Study ID Numbers: |
ADX-914-202 |
First Posted: | August 19, 2022 Key Record Dates |
Last Update Posted: | February 20, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Atopic Dermatitis Eczema Dermatitis |
Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic |
Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |